Clinical trials: Cholangitis, Sclerosing
Primary Biliary Cholangitis, Primary Sclerosing Cholangitis
The Effect of Bezafibrate on Cholestatic Itch
Randomized double blind placebo controlled trial to evaluate the antipruritic effect of bezafibrate in patients with moderate to severe cholestatic itch.
- Conditions
- Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Secondary Sclerosing Cholangitis
- Trial name
- FITCH (NCT02701166)
- Testing
- Bezafibrate
- Where
- 9 sites in Netherlands, Spain
- Volunteers
- 84 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Primary Sclerosing Cholangitis
A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis
The purpose of this study is to determine whether Vancomycin or Metronidazole is safe and beneficial in the treatment of Primary Sclerosing Cholangitis.
- Trial name
- PSC (NCT01085760)
- Testing
- Vancomycin, Metronidazole
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Mayo Clinic
Primary Sclerosing Cholangitis
Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.
Primary objective: To evaluate the efficacy of hymecromone plus standard of care compared with standard of care alone in the treatment of adolescents and adults with primary sclerosing cholangitis (PSC).
- Trial name
- HAAPS (NCT05295680)
- Testing
- Hymecromone
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Aparna Goel
Primary Sclerosing Cholangitis, Inflammatory Bowel Disease
Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease
The purpose of this study is to evaluate the efficacy and safety of vedolizumab intravenous (IV) in non-end-stage primary sclerosing cholangitis (PSC) participants with underlying inflammatory bowel disease (IBD).
- Trial name
- NCT03035058
- Testing
- Vedolizumab
- Sponsor
- Takeda
Primary Sclerosing Cholangitis (PSC)
Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC)
This was a phase 2, double-blind (DB), placebo-controlled trial in participants with primary sclerosing cholangitis to evaluate the effect of obeticholic acid on liver biochemistry, in particular, serum alkaline phosphatase; and…
- Trial name
- AESOP (NCT02177136)
- Testing
- Obeticholic Acid (OCA)
- Where
- 36 sites in United States, Italy
- Volunteers
- 77 people
- Sponsor
- Intercept Pharmaceuticals
Primary Sclerosing Cholangitis, PSC
Quantitative Magnetic Resonance Imaging in Biliary Disease: Health Economics Study
This is a health economic study on using quantitative magnetic resonance imaging in biliary disease. It is an observational study aiming to recruit 40 patients with Primary Sclerosing Cholangitis (PSC) in 12 months.
- Trial name
- BISECT (NCT04015310)
- Testing
- Quantitative Multi parametric MRI and enhanced MRCP
- Sponsor
- Perspectum
Biliary Stricture, Pancreas Cancer
Volumetric Laser Endomicroscopy's (VLE) Diagnostic Accuracy Validation Study: Impact on Clinical Management Study
The purpose of this study is to assess the interobserver agreement (IOV) for pancreatico-biliary Volumetric Laser Endomicroscopy (VLE) de-identified clips using the new VLE criteria.
- Conditions
- Biliary Stricture, Pancreas Cancer, Cholangiocarcinoma, Bile Duct Cancer
- Trial name
- VLE-IOV (NCT03951324)
- Testing
- Interobserver agreement or Interrater agreement
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Innovative Digestive Health Education and Research Inc
Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC)
Vancomycin Efficacy in Response to Dysbiosis in Atypical Colitis
The goal of this clinical trial is to learn how oral vancomycin therapy may contribute in treating paediatric inflammatory bowel disease, particularly atypical ulcerative colitis and PSC-associated colitis.
- Conditions
- Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC), Pediatric Inflammatory Bowel Diseases
- Trial name
- VERDA (NCT07646223)
- Testing
- Oral Vancomycin
- Where
- Finland
- Volunteers
- 140 people
- Sponsor
- Tampere University Hospital
Primary Sclerosing Cholangitis
A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis
The objectives of this study is to Evaluate the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Patients with Primary Sclerosing Cholangitis
- Trial name
- NCT06095986
- Testing
- Aramchol meglumine
- Where
- United States
- Sponsor
- Galmed Pharmaceuticals Ltd
Hepatobiliary Diseases
Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases
The investigators hypothesize that the extent of sulfation of toxic BAs and their urinary elimination can be used as a biomarker to predict the severity and prognosis of hepatobiliary diseases.
- Trial name
- NCT01200082
- Where
- United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Primary Sclerosing Cholangitis
Probiotics in Patients With Primary Sclerosing Cholangitis
PSC is a progressive liver disease without effective medical treatment. There is often co-existent ulcerative colitis. Probiotics (bacterial food supplements) have been shown to benefit patients with ulcerative colitis.
- Trial name
- NCT00161148
- Testing
- Probiotics
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- UMC Utrecht
PSC
Colangioids to Define the Genetic Factors Involved in Atypical Primary Sclerosing Cholangitis
Primary sclerosing cholangitis (PSC) is a rare, progressive and often fatal disease of the intrahepatic or extrahepatic bile ducts, with an estimated prevalence in Western countries of 1/10,000.
- Trial name
- CILIA (NCT06865924)
- Testing
- Use of assembloids as in vitro models to test new pharmacological approaches
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
The purpose of this study is to determine whether the investigational treatment (maralixibat) is safe and effective in pediatric and adult participants who have cholestatic liver disease with pruritus that has been refractory to…
- Trial name
- NCT06553768
- Testing
- Maralixibat
- Where
- 23 sites in United States, Brazil and 8 more
- Volunteers
- 90 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
A Pilot Study Examining Diet in Primary Sclerosing Cholangitis
This research study is exploring the effects of dietary intervention in PSC. Study participants will be randomly assigned to either the Specific Carbohydrate Diet (SCD) or a vegan/low-sulfur diet for 8 weeks; the entire study…
- Trial name
- DINER (NCT04678219)
- Testing
- Dietary Intervention
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Brigham and Women's Hospital
Primary Sclerosing Cholangitis (PSC)
S-adenosylmethionine (SAMe) in Patients With Primary Sclerosing Cholangitis (PSC)
The aim of this study is to investigate clinical effects (liver biochemistries, health-related quality of life, liver stiffness) and underlying mechanisms of hepatoprotection of S-adenosylmethionine in patients with primary…
- Trial name
- NCT06026865
- Testing
- S-Adenosyl-L-methionine (SAMe)
- Where
- Poland
- Volunteers
- 60 people
- Sponsor
- Medical University of Warsaw
Primary Sclerosing Cholangitis
CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)
A phase II Study of CS0159 in Chinese patients with PSC(Primary Sclerosing Cholangitis)
- Trial name
- NCT05896137
- Testing
- CS0159
- Where
- 11 sites in China
- Volunteers
- 50 people
- Sponsor
- Cascade Pharmaceuticals, Inc
Primary Sclerosing Cholangitis
A Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis (PSC)
The purpose of this study is to determine whether curcumin, a drug and naturally-occurring plant compound, is safe and effective in the treatment of primary sclerosing cholangitis (PSC).
- Trial name
- NCT02978339
- Testing
- Curcumin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- John E. Eaton
Rheumatoid Arthritis, Ankylosing Spondylitis
Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases
TRANSREG will assess the safety and biological efficacy of low-dose IL2 as a Treg inducer in a set of 14 autoimmune and auto-inflammatory diseases, with the aim to select diseases in which further therapeutic development will be…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus, Psoriasis
- Trial name
- TRANSREG (NCT01988506)
- Testing
- Interleukin 2
- Where
- 11 sites in France
- Volunteers
- 81 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Primary Sclerosing Cholangitis, Inflammatory Bowel Diseases
Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study
PSC is a liver disease that has no medical cure. Patients with PSC are at a greatly increased risk of cancer and infection. Additionally, many patients require a liver transplant.
- Trial name
- NCT05912387
- Testing
- Rosuvastatin
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Stanford University
Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC)
Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects
CM-101 is developed as treatment for medical conditions involving inflammatory and fibrotic mechanisms such as non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC), Systemic Sclerosis (SSc)
- Trial name
- NCT06037577
- Testing
- CM-101
- Where
- Israel
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- ChemomAb Ltd.